Literature DB >> 29668328

Use of Placebo in Clinical Trials of Psychotropic Medication.

Mehrul Hasnain1, Abraham Rudnick2, Weldon S Bonnell3, Gary Remington4, Raymond W Lam5.   

Abstract

This position paper has been substantially revised by the Canadian Psychiatric Association's Research Committee and approved for republication by the CPA's Board of Directors on March 31, 2017. The original position paper1 was developed by the Scientific and Research Council and approved by the Board of Directors on October 4, 1996.

Mesh：

Substances：

Year:  2018        PMID： 29668328      PMCID： PMC5912304          DOI： 10.1177/0706743717752917

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN： 0706-7437            Impact factor:   4.356


  21 in total

1.  Why has the antidepressant-placebo difference in antidepressant clinical trials diminished over the past three decades?

Authors:  Arif Khan; Amritha Bhat; Russell Kolts; Michael E Thase; Walter Brown
Journal:  CNS Neurosci Ther       Date:  2010-04-16       Impact factor: 5.243

Review 2.  Alternatives to placebo-controlled trials.

Authors:  David L Streiner
Journal:  Can J Neurol Sci       Date:  2007-03       Impact factor: 2.104

3.  Ethical obligations and the use of placebo controls.

Authors:  Kathleen Cranley Glass
Journal:  Can J Psychiatry       Date:  2008-07       Impact factor: 4.356

4.  Increasing placebo response in antipsychotic drug trials: let's stop the vicious circle.

Authors:  Stefan Leucht; Stephan Heres; John M Davis
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

Review 5.  Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses.

Authors:  Mark Sinyor; Anthony J Levitt; Amy H Cheung; Ayal Schaffer; Alex Kiss; Yekta Dowlati; Krista L Lanctôt
Journal:  J Clin Psychiatry       Date:  2010-01-26       Impact factor: 4.384

Review 6.  Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.

Authors:  Scott W Woods; Ralitza V Gueorguieva; C Bruce Baker; Robert W Makuch
Journal:  Arch Gen Psychiatry       Date:  2005-09

Review 7.  The placebo arm in clinical studies for treatment of psychiatric disorders: a regulatory dilemma.

Authors:  Christine Gispen-de Wied; Violeta Stoyanova; Yang Yu; Maria Isaac; Luca Pani; Fernando de Andres-Trelles
Journal:  Eur Neuropsychopharmacol       Date:  2012-06-15       Impact factor: 4.600

8.  Antidepressants versus placebo in major depression: an overview.

Authors:  Arif Khan; Walter A Brown
Journal:  World Psychiatry       Date:  2015-10       Impact factor: 49.548

9.  What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?

Authors:  Aaron S Kemp; Nina R Schooler; Amir H Kalali; Larry Alphs; Ravi Anand; George Awad; Michael Davidson; Sanjay Dubé; Larry Ereshefsky; Georges Gharabawi; Andrew C Leon; Jean-Pierre Lepine; Steven G Potkin; An Vermeulen
Journal:  Schizophr Bull       Date:  2008-08-22       Impact factor: 9.306

Review 10.  Newer generation antidepressants for depressive disorders in children and adolescents.

Authors:  Sarah E Hetrick; Joanne E McKenzie; Georgina R Cox; Magenta B Simmons; Sally N Merry
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.